Previous close | 17.18 |
Open | 17.23 |
Bid | 16.85 x 200 |
Ask | 16.96 x 100 |
Day's range | 16.55 - 17.23 |
52-week range | 8.69 - 24.13 |
Volume | |
Avg. volume | 573,553 |
Market cap | 696.744M |
Beta (5Y monthly) | 1.09 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
UroGen Pharma ( NASDAQ:URGN ) First Quarter 2024 Results Key Financial Results Revenue: US$18.8m (up 9.2% from 1Q...
Insight into UroGen Pharma's First Quarter Financial Performance and Strategic Highlights